Department of Gastroenterology, University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Pancreas. 2010 Oct;39(7):989-93. doi: 10.1097/MPA.0b013e3181d91936.
The aim of this study was to investigate the effect of S-1 on the prognosis of advanced pancreatic cancer.
In total, 112 patients with pancreatic cancer who received chemotherapy between April 2001 and April 2007 were divided into 2 groups: PreS-1 (53 patients who started chemotherapy before January 2005) and PostS-1 (59 patients who started chemotherapy after February 2005, the time of S-1 introduction). Patient characteristics and clinical outcomes were compared, and prognostic factors were analyzed.
Patient characteristics did not significantly differ between the 2 groups. S-1 was administered as a second-line monotherapy in 5.7% of the PreS-1 group and combined with gemcitabine as a first-line therapy in 27.1% or as second-line monotherapy in 23.7% in the PostS-1 group. Both progression-free survival and overall survival improved after introduction of S-1 (median progression-free survival, 4.4 and 5.3 months; P = 0.043; median overall survival, 9.5 and 13.1 months; P = 0.048 in PreS-1 and PostS-1 groups, respectively). Multivariate analysis revealed that the PostS-1 group (hazards ratio, 0.52; P = 0.003), performance status, and carcinoembryonic antigen were significant prognostic factors for survival.
Introduction of S-1 may improve the prognosis of Japanese patients with advanced pancreatic cancer.
本研究旨在探讨替吉奥（S-1）对晚期胰腺癌预后的影响。
本研究纳入了 2001 年 4 月至 2007 年 4 月期间接受化疗的 112 例胰腺癌患者，将其分为 PreS-1 组（53 例，2005 年 1 月前开始化疗）和 PostS-1 组（59 例，2005 年 2 月后开始化疗，即 S-1 引入时间）。比较了两组患者的特征和临床结局，并分析了预后因素。
两组患者的特征无显著差异。PreS-1 组中，S-1 作为二线单药治疗的比例为 5.7%，与吉西他滨联合作为一线治疗的比例为 27.1%，或作为二线单药治疗的比例为 23.7%。PostS-1 组中，S-1 作为二线单药治疗的比例为 5.7%，与吉西他滨联合作为一线治疗的比例为 27.1%，或作为二线单药治疗的比例为 23.7%。S-1 引入后，无进展生存期和总生存期均得到改善（中位无进展生存期分别为 4.4 个月和 5.3 个月，P = 0.043；中位总生存期分别为 9.5 个月和 13.1 个月，P = 0.048）。多因素分析显示，PostS-1 组（风险比，0.52；P = 0.003）、体力状态和癌胚抗原是生存的显著预后因素。
S-1 的引入可能改善日本晚期胰腺癌患者的预后。
